Cardio-Oncology

Abstract Background The relevance of cardiovascular disease in people with a history of cancer has increased in parallel with dramatic improvements in cancer-specific outcomes. There is an urgent need to improve the evidence underpinning cardio-oncology practice. Research prioritisation is essential and needs to account for multidisciplinary healthcare professional (HCP) perspectives, as well as …

Cancer-associated thrombosis is one of the most common and serious complications in oncology patients, contributing significantly to morbidity and mortality. This prothrombotic state is driven by cancer-related factors, systemic inflammation, and treatment-induced endothelial injury. Anticoagulation management in these patients is challenging, as both thrombotic and bleeding risks must be careful…

Breast cancer treatment may be associated with adverse cardiovascular effects. Pulse wave velocity (PWV) is a marker of arterial stiffness and a validated predictor of cardiovascular events. The aim of this study was to evaluate whether a history of breast cancer (HBC), beyond the first year after diagnosis, is associated with higher PWV in middle-aged women in a primary prevention setting. Women…

Chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (ABI) have a higher cardiovascular (CV) event-related hospitalization risk than those treated with enzalutamide (ENZA). This study aimed to assess CV event risk in chemotherapy-naïve patients with mCRPC treated with ENZA or ABI and to provide outcome data based on CV disease (CVD) his…

Paediatric cancer survival rates continue to improve with overall long-term survival now over 80%. A significant proportion of conventional and novel cancer therapies have cardiovascular toxicities which become increasingly relevant as long-term survival improves. At present, within the Italian healthcare setting, a systematic approach to the detection and management of cardiotoxicity in paediatr…

Myelofibrosis (MF) is a type of myeloproliferative neoplasm (MPN) that is associated with significant morbidity and mortality including progression to acute leukemia and cardiovascular disease (CVD). High-output heart failure (HOHF) has been previously associated with MF, though its impact on outcomes is unknown. To investigate the impact of HOHF on outcomes among patients with MF. This was a mul…

Anthracyclines significantly improve overall survival and play a vital role in the treatment of breast cancer. However, they are associated with cardiac dysfunction, which is often irreversible. Although anthracycline-induced cardiotoxicity (AIC) is dose-dependent, the difference in susceptibility patterns suggests the role of pharmacogenomics. Several studies explored the role of genetic variant…

Previous studies have suggested the potential effect of psychological stress related to cancer diagnosis on cardiovascular mortality. This study aimed to investigate the temporal trends of cardiovascular risk before and after cancer diagnosis using a deep learning model applied to 12-lead electrocardiograms (ECGs). We developed a deep learning model using a publicly available large-scale dataset …

Nedaplatin (NDP), a cisplatin derivative, is widely employed in the treatment of solid tumours. Commonly reported adverse effects include hypersensitivity, myelosuppression and nephrotoxicity. To date, QT-interval prolongation and polymorphic ventricular tachyarrhythmia have not been attributed to NDP. A 41-year-old Asian woman was referred to our institution with abdominal pain, diarrhoea and vo…

Sleep disturbances during breast cancer (BC) treatment may represent a modifiable contributor to left ventricular ejection fraction (LVEF) decline during BC treatment. We investigated the association of sleep disturbance and LVEF decline in a prospective cohort of 247 women with non-metastatic BC scheduled for chemotherapy as part of the UPBEAT study conducted through the Wake Forest NCI Communit…